Tandem Diabetes Care Appoints Peyton Howell to Board of Directors
July 29 2020 - 4:05PM
Business Wire
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced the
appointment of Peyton Howell as an independent member of its board
of directors effective August 3, 2020. Ms. Howell brings to the
Tandem board extensive reimbursement, health insurance, and patient
access experience across a broad range of disease states in the
hospital, physician, pharmacy and home care settings.
“Peyton brings significant expertise to our Board, drawing on
more than 25 years of healthcare and leadership experience,” said
John Sheridan, President and CEO. “Her appointment reflects our
commitment to ensuring that we have a broad mix of skills and
perspectives on Tandem’s board, and we are confident she will
provide valuable insight from across the healthcare landscape as we
continue to execute our strategy to lead in insulin therapy
management.”
Ms. Howell is currently the Chief Commercial and Strategy
Officer at Parexel International, a leading global clinical
research organization servicing the life sciences industry. Prior
to joining Parexel, Ms. Howell held a wide range of senior
leadership positions at AmerisourceBergen, including leading Global
Sourcing and Manufacturer Relations and advancing specialty and
biotech products and solutions for physicians, health systems and
specialty pharmacies. She was a founder and President of Lash
Group, a patient support services company, and an early pioneer of
programs to support patient access, reimbursement, and adherence to
new therapies including services related to diabetes, such as
patient assistance and reimbursement support for continuous glucose
monitors. Ms. Howell was President of Lash Group for nearly a
decade following its acquisition by AmerisourceBergen.
Ms. Howell is a recognized national speaker on health policy,
patient access and reimbursement issues. She has served as Director
of the AmerisourceBergen Foundation, the National Association of
Chain Drug Stores Foundation, and the Healthcare Distribution
Alliance Foundation. Ms. Howell received a Bachelor of Arts in
Speech Communication from The University of Illinois, Champaign and
a Master’s of Health Administration from The Ohio State
University.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem’s flagship product,
the t:slim X2™ insulin pump, is capable of remote software updates
using a personal computer and features integrated continuous
glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark and t:slim X2 is
a trademark of Tandem Diabetes Care, Inc.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, and $TNDM. Follow Tandem Diabetes Care on Facebook at
www.facebook.com/TandemDiabetes. Follow Tandem Diabetes Care on
LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200729005958/en/
Media Contact: Steve Sabicer 714-907-6264
ssabicer@thesabicergroup.com
Investor Contact: Susan Morrison 858-366-6900 x7005
IR@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Sep 2023 to Sep 2024